Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,099 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Strong, but Age-Dependent, Protection Elicited by a Deoxyribonucleic Acid/Modified Vaccinia Ankara Simian Immunodeficiency Virus Vaccine.
Chamcha V, Kannanganat S, Gangadhara S, Nabi R, Kozlowski PA, Montefiori DC, LaBranche CC, Wrammert J, Keele BF, Balachandran H, Sahu S, Lifton M, Santra S, Basu R, Moss B, Robinson HL, Amara RR. Chamcha V, et al. Among authors: moss b. Open Forum Infect Dis. 2016 Feb 11;3(1):ofw034. doi: 10.1093/ofid/ofw034. eCollection 2016 Jan. Open Forum Infect Dis. 2016. PMID: 27006959 Free PMC article.
Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara.
Hirsch VM, Fuerst TR, Sutter G, Carroll MW, Yang LC, Goldstein S, Piatak M Jr, Elkins WR, Alvord WG, Montefiori DC, Moss B, Lifson JD. Hirsch VM, et al. Among authors: moss b. J Virol. 1996 Jun;70(6):3741-52. doi: 10.1128/JVI.70.6.3741-3752.1996. J Virol. 1996. PMID: 8648709 Free PMC article.
Comparison of the immunogenicity and efficacy of a replication-defective vaccinia virus expressing antigens of human parainfluenza virus type 3 (HPIV3) with those of a live attenuated HPIV3 vaccine candidate in rhesus monkeys passively immunized with PIV3 antibodies.
Durbin AP, Cho CJ, Elkins WR, Wyatt LS, Moss B, Murphy BR. Durbin AP, et al. Among authors: moss b. J Infect Dis. 1999 Jun;179(6):1345-51. doi: 10.1086/314769. J Infect Dis. 1999. PMID: 10228053
Immunization with a modified vaccinia virus expressing simian immunodeficiency virus (SIV) Gag-Pol primes for an anamnestic Gag-specific cytotoxic T-lymphocyte response and is associated with reduction of viremia after SIV challenge.
Seth A, Ourmanov I, Schmitz JE, Kuroda MJ, Lifton MA, Nickerson CE, Wyatt L, Carroll M, Moss B, Venzon D, Letvin NL, Hirsch VM. Seth A, et al. Among authors: moss b. J Virol. 2000 Mar;74(6):2502-9. doi: 10.1128/jvi.74.6.2502-2509.2000. J Virol. 2000. PMID: 10684264 Free PMC article.
Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140.
Earl PL, Sugiura W, Montefiori DC, Broder CC, Lee SA, Wild C, Lifson J, Moss B. Earl PL, et al. Among authors: moss b. J Virol. 2001 Jan;75(2):645-53. doi: 10.1128/JVI.75.2.645-653.2001. J Virol. 2001. PMID: 11134278 Free PMC article.
Long, S. A. Lee, J. Peterson, S. Chakrabarti, R. W. Doms, and B. Moss, J. Virol. 68:3015-3026, 1994). Here we compared the antibody responses of rabbits to gp120 and gp140 that had been produced and purified in an identical manner. ...
Long, S. A. Lee, J. Peterson, S. Chakrabarti, R. W. Doms, and B. Moss, J. Virol. 68:3015-3026, 1994). Here we compared the ant …
Elicitation of high-frequency cytotoxic T-lymphocyte responses against both dominant and subdominant simian-human immunodeficiency virus epitopes by DNA vaccination of rhesus monkeys.
Barouch DH, Craiu A, Santra S, Egan MA, Schmitz JE, Kuroda MJ, Fu TM, Nam JH, Wyatt LS, Lifton MA, Krivulka GR, Nickerson CE, Lord CI, Moss B, Lewis MG, Hirsch VM, Shiver JW, Letvin NL. Barouch DH, et al. Among authors: moss b. J Virol. 2001 Mar;75(5):2462-7. doi: 10.1128/JVI.75.5.2462-2467.2001. J Virol. 2001. PMID: 11160750 Free PMC article.
Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination.
Barouch DH, Santra S, Kuroda MJ, Schmitz JE, Plishka R, Buckler-White A, Gaitan AE, Zin R, Nam JH, Wyatt LS, Lifton MA, Nickerson CE, Moss B, Montefiori DC, Hirsch VM, Letvin NL. Barouch DH, et al. Among authors: moss b. J Virol. 2001 Jun;75(11):5151-8. doi: 10.1128/JVI.75.11.5151-5158.2001. J Virol. 2001. PMID: 11333896 Free PMC article.
Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.
Amara RR, Villinger F, Altman JD, Lydy SL, O'Neil SP, Staprans SI, Montefiori DC, Xu Y, Herndon JG, Wyatt LS, Candido MA, Kozyr NL, Earl PL, Smith JM, Ma HL, Grimm BD, Hulsey ML, Miller J, McClure HM, McNicholl JM, Moss B, Robinson HL. Amara RR, et al. Among authors: moss b. Science. 2001 Apr 6;292(5514):69-74. doi: 10.1126/science.1058915. Science. 2001. PMID: 11393868
Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.
Amara RR, Villinger F, Altman JD, Lydy SL, O'Neil SP, Staprans SI, Montefiori DC, Xu Y, Herndon JG, Wyatt LS, Candido MA, Kozyr NL, Earl PL, Smith JM, Ma HL, Grimm BD, Hulsey ML, McClure HM, McNicholl JM, Moss B, Robinson HL. Amara RR, et al. Among authors: moss b. Vaccine. 2002 May 6;20(15):1949-55. doi: 10.1016/s0264-410x(02)00076-2. Vaccine. 2002. PMID: 11983252 Review.
1,099 results